Sunitinib rechallenge in metastatic renal cell carcinoma patients (Q37812061)

23 August 2017

title

Sunitinib rechallenge in metastatic renal cell carcinoma patients (English)

1 reference

metastatic renal cell carcinoma

23 August 2017

0 references

1 reference

1 reference

Bernard Escudier

1 reference

23 August 2017

Toni K Choueiri

1 reference

23 August 2017

Ivan N Zama

1 reference

23 August 2017

Thomas E Hutson

1 reference

23 August 2017

Paul Elson

1 reference

23 August 2017

James M Cleary

1 reference

23 August 2017

Daniel Y C Heng

1 reference

23 August 2017

Nikhil Ramaiya

1 reference

23 August 2017

M Dror Michaelson

1 reference

23 August 2017

Jorge A Garcia

1 reference

23 August 2017

Jennifer J Knox

1 reference

23 August 2017

Brian I Rini

1 reference

23 August 2017

language of work or name

English

0 references

publication date

2 November 2010

1 reference

23 August 2017

1 reference

23 August 2017

volume

116

1 reference

23 August 2017

1 reference

23 August 2017

page(s)

5400-5406

1 reference

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25583

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25583

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25583

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25583

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25583

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25583

Sequential therapy in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25583

Resistance to targeted therapy in renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25583

Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25583

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25583

Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25583

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25583

Effect of re-treatment with gefitinib ('Iressa', ZD1839) after acquisition of resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25583

Remarkable effect of gefitinib retreatment in a patient with nonsmall cell lung cancer who had a complete response to initial gefitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25583

Heterogeneity and progression of renal cell carcinomas as revealed by DNA cytofluorometry and the significance of the presence of polyploid cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25583

The clonal evolution of tumor cell populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25583

Evolution of HIV resistance during treatment interruption in experienced patients and after restarting a new therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25583

HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: a view from the clinic and ex vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25583

High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25583

Detection of mutations in EGFR in circulating lung-cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25583

Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25583

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25583

7 January 2021

Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25583

7 January 2021

Recurrent ovarian carcinoma: retreatment utilizing combination chemotherapy including cis-diamminedichloroplatinum in patients previously responding to this agent

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25583

7 January 2021

Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25583

7 January 2021

Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25583

7 January 2021

Retreatment of lung adenocarcinoma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: a report of three cases.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25583

7 January 2021

Intratumoral heterogeneity of DNA content in renal cell carcinoma and its prognostic significance

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25583

7 January 2021

Cancer as a robust system: implications for anticancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25583

7 January 2021

Identifiers

DOI

10.1002/CNCR.25583

1 reference

23 August 2017

1 reference